Amiodarone Drug Class: How Class III Antiarrhythmics Work

Amiodarone is classified as a Class III antiarrhythmic drug, a category defined by its ability to prolong the heart’s electrical recovery phase by blocking potassium channels. That classification, however, only tells part of the story. Unlike most antiarrhythmics that fit neatly into one slot, amiodarone acts on sodium channels, calcium channels, and adrenergic receptors as well, giving it a pharmacological profile so broad that some cardiologists consider it a class of its own. Originally developed in the early 1960s as an anti-anginal agent to relieve chest pain, it was only later recognized as one of the most effective rhythm-control drugs available, useful for both atrial and ventricular arrhythmias.¹

What Class III Actually Means for Amiodarone

Antiarrhythmic drugs are grouped using the Vaughan-Williams classification, which sorts them by their primary electrical effect on heart cells. Class III drugs work mainly by blocking potassium channels, which slows the repolarization phase of the cardiac action potential. In practical terms, this means the heart muscle takes slightly longer to reset between beats, which helps suppress the chaotic electrical signals that cause arrhythmias. Amiodarone’s Class III effect centers on its inhibition of HERG potassium channels, which carry a current called I_Kr that is critical to this repolarization step.²

But amiodarone does not stop there. With long-term use, the drug also reduces other potassium currents and a transient outward current, leading to a moderate lengthening of the action potential that is consistent across different heart rates. This is a meaningful distinction from some other drugs, where the effect changes depending on how fast the heart is beating.³ Its additional effects on sodium channels (a Class I property), calcium channels (Class IV), and beta-adrenergic receptors (Class II) are what make it so difficult to pigeonhole. This multi-channel blockade is widely thought to be the reason amiodarone controls a wider range of arrhythmias than drugs that target only one channel type.

Why Amiodarone Has an Unusually Low Risk of Triggering New Arrhythmias

One of the paradoxes of antiarrhythmic drugs is that they can sometimes cause the very arrhythmias they are meant to prevent. A particularly dangerous example is torsade de pointes (TdP), a rapid, twisting rhythm that can be fatal. Many Class III drugs carry a meaningful risk of TdP because blocking potassium channels can lengthen the QT interval unevenly across different layers of heart muscle, creating the electrical instability that triggers it.

Amiodarone is a striking exception. Despite prolonging the QT interval, it rarely causes TdP. An animal study comparing amiodarone to its structural cousin dronedarone found that while both drugs lengthened the QT interval by a similar degree, amiodarone produced a more uniform lengthening across the heart wall. Dronedarone triggered TdP in half the animals tested; amiodarone triggered it in none, and no abnormal early electrical afterbeats were recorded in any of the amiodarone-treated animals.⁴ This safety advantage has been recognized since the drug’s early clinical use and is one of the key reasons it remains a first-line choice despite its other toxicities.⁵

Where Amiodarone Is Used Clinically

Amiodarone’s clinical reach is broad, spanning two major arrhythmia categories: atrial fibrillation and life-threatening ventricular arrhythmias.

Atrial Fibrillation

For maintaining a normal heart rhythm in people with atrial fibrillation (AF), amiodarone consistently outperforms other antiarrhythmics. In a head-to-head trial, about 35 percent of patients on amiodarone experienced a recurrence of AF over roughly 16 months, compared with 63 percent of patients on sotalol or propafenone.⁶ A substudy from the large AFFIRM trial confirmed this advantage: at one year, about 60 percent of patients were successfully maintained on amiodarone, versus roughly a quarter on Class I agents and just under 40 percent on sotalol.⁷

In patients with heart failure and AF, amiodarone also showed the ability to spontaneously convert the irregular rhythm back to normal. In the CHF-STAT trial, roughly a third of heart failure patients on amiodarone converted to a normal rhythm, compared with fewer than one in ten on placebo. The drug also prevented new episodes of AF from developing in patients who started the trial in normal rhythm.⁸

Ventricular Arrhythmias and Cardiac Arrest

Amiodarone is a standard drug used during cardiac arrest when the heart is in ventricular fibrillation or pulseless ventricular tachycardia and repeated electrical shocks have failed to restore a normal rhythm.⁹ In a landmark trial, patients who received intravenous amiodarone during out-of-hospital cardiac arrest were significantly more likely to survive to hospital admission: 44 percent versus 34 percent for placebo.¹⁰

A meta-analysis pooling data from randomized trials confirmed that amiodarone improves the odds of surviving to hospital admission by about 40 percent compared with placebo or another antiarrhythmic. However, neither survival to hospital discharge nor neurological outcomes were significantly improved, a sobering reminder that getting a pulse back is only the first hurdle in cardiac arrest survival.¹¹

The Iodine Problem and Thyroid Dysfunction

Amiodarone’s chemical structure contains two iodine atoms bonded to a benzene ring.¹² A standard 200 mg daily dose releases roughly 6 mg of free iodine into the body, far more than the 0.15 mg an adult typically needs. This massive iodine load is the primary driver of one of the drug’s most common side effects: thyroid dysfunction.

The thyroid can respond in two opposite directions. Some patients develop hypothyroidism, where the gland shuts down from iodine overload. Others develop thyrotoxicosis, where the gland goes into overdrive. These two outcomes tend to split along geographic and clinical lines: hypothyroidism is more common in regions where dietary iodine is already sufficient, and in people with pre-existing autoimmune thyroid disease like Hashimoto’s thyroiditis. Thyrotoxicosis is more common in iodine-deficient areas.¹³

Thyrotoxicosis itself comes in two forms. Type 1 occurs in people who already have an underlying thyroid problem, such as a nodular goiter, and represents the thyroid overproducing hormones in response to excess iodine. Type 2 occurs in people with previously healthy thyroids and results from amiodarone directly damaging thyroid tissue, causing stored hormone to leak out. Telling them apart matters because the treatments are different, and in practice, many patients have features of both.¹⁴

Pulmonary Toxicity

Lung damage is the most feared complication of amiodarone therapy. It typically shows up as pneumonitis, with cough, shortness of breath, and diffuse shadowing on chest imaging. The onset can be gradual over weeks or months, or it can be rapid and severe, sometimes progressing to acute respiratory distress.¹⁵

Clinicians draw a distinction between two categories of lung involvement. The first, sometimes called the “amiodarone effect,” is a low-grade lipid-laden change in lung cells that is almost universal among patients on the drug and usually causes no symptoms. The second, true amiodarone pulmonary toxicity, encompasses a range of inflammatory patterns from eosinophilic pneumonia and organizing pneumonia to interstitial fibrosis and diffuse bleeding in the lung. Three mechanisms have been proposed: a direct toxic effect on lung tissue, an immune-mediated reaction, and activation of the renin-angiotensin system in the lung.¹⁶ Diagnosis requires ruling out infection and cancer first, since the symptoms and imaging findings can look alike.¹⁷

Effects on the Eyes, Skin, and Liver

Eyes

Nearly all patients on long-term amiodarone develop corneal microdeposits, tiny whorl-shaped patterns visible on slit-lamp examination. In a study of over a hundred patients, 98 percent had them. Despite how common they are, they rarely affect vision: only about 6 percent reported visual symptoms such as glare sensitivity or halos, and none lost visual acuity.¹⁸ A more serious but less common concern is optic neuropathy, which involves swelling of the optic nerve and can lead to permanent vision loss. In a review of reported cases, the average time from starting amiodarone to vision loss was about nine months, and roughly one in five affected patients developed legal blindness in at least one eye.¹⁹

Skin

Photosensitivity is common enough that early clinical series found it in every patient studied, suggesting it is a direct phototoxic reaction rather than an allergic one.²⁰ With prolonged use, some patients develop a distinctive blue-gray discoloration of sun-exposed skin. Electron probe analysis of these deposits has found high concentrations of iodine, consistent with amiodarone or its metabolite accumulating in the skin. Because the drug clears so slowly from fatty tissue, the discoloration can persist for months or years after stopping the drug.²¹

Liver

Amiodarone can cause a spectrum of liver injury. Mild elevations in liver enzymes are relatively common during treatment. Under the microscope, affected liver tissue often shows fatty change, cellular degeneration, and a pattern that resembles alcoholic hepatitis, sometimes called “pseudoalcoholic” liver disease. Electron microscopy reveals characteristic phospholipid-laden bodies inside cells, a hallmark of the drug’s ability to disrupt lipid metabolism.²² This phospholipid accumulation appears to be a general property of the drug’s chemical class (cationic amphiphilic compounds) rather than something unique to amiodarone, while the more destructive pseudoalcoholic changes seem to occur in patients who are less able to metabolize the drug normally.²³

Why the Drug Stays in Your Body for Months

Amiodarone is extremely fat-soluble, which means it distributes widely into body tissues, especially fat and skeletal muscle. During long-term treatment, these tissues gradually fill up with the drug. When you stop taking it, the half-life can stretch to around 100 days, meaning it takes months for the body to clear it. The volume of distribution is enormous and highly variable between individuals.²⁴ This has real clinical consequences: if a serious side effect develops, simply stopping the drug does not provide quick relief. The slow tissue washout explains why photosensitivity, skin discoloration, and thyroid abnormalities can appear or persist long after the last dose. It also means drug interactions, such as the potentiation of warfarin’s blood-thinning effect, can linger for weeks after amiodarone is discontinued.²⁵

Monitoring Requirements

Because amiodarone can affect so many organ systems, patients on the drug need regular surveillance. Guidelines call for a baseline workup before starting therapy and periodic checks during treatment:

Thyroid function: tested before starting and every six months during treatment.
Liver enzymes: tested before starting and every six months.
Chest X-ray: done at baseline and annually.
Lung function testing: performed based on symptoms rather than on a fixed schedule.
Heart evaluation and ECG: done at baseline and annually.

Despite the clarity of these recommendations, adherence in real-world practice is often patchy.²⁶ Ophthalmologic monitoring is another area of debate. While the corneal deposits are nearly universal and benign, the possibility of optic neuropathy has led some experts to recommend close eye surveillance throughout treatment.²⁷

Dronedarone and the Search for a Safer Alternative

Dronedarone was developed as a deliberate modification of amiodarone. The key structural change was removing the iodine atoms, which were thought to be responsible for much of the thyroid and organ toxicity. The result is a drug with similar electrophysiological properties but a considerably shorter half-life and, in theory, a cleaner side-effect profile.

In practice, the trade-off is effectiveness. A retrospective cohort study found that patients on dronedarone had a higher rate of cardiovascular-related hospitalizations than those on amiodarone, roughly 13 percent versus 8 percent.²⁸ Data from the EAST-AFNET 4 trial showed that dronedarone tended to be used in patients with less severe heart disease, while amiodarone was reserved for sicker patients with more heart failure and persistent AF. Even so, dronedarone was associated with a lower rate of the combined outcome of cardiovascular death, stroke, and heart failure hospitalization in a multivariate analysis.²⁹ Dronedarone is contraindicated in patients with severe heart failure, precisely the population where amiodarone is often most needed, which limits its role as a true replacement.

Use in Pregnancy and Children

Pregnancy

Amiodarone and its main metabolite cross the placenta, exposing the fetus to both the drug and a significant iodine load. Among 64 reported pregnancies in which the mother took amiodarone, about 17 percent of the infants were born hypothyroid. All cases were transient, and most resolved without treatment or with a short course of thyroid hormone replacement. However, some of these infants, including some who were not hypothyroid, showed subtle neurodevelopmental differences, raising concern about a possible direct effect of the drug on the developing brain.³⁰ The drug also appears in breast milk in substantial quantities, though in the few cases followed, breastfeeding did not cause thyroid changes in the newborn. Current guidance treats pregnancy and breastfeeding not as absolute contraindications but as situations requiring the lowest effective dose and close thyroid monitoring of both mother and baby.³¹

Children

Intravenous amiodarone is used in children with life-threatening arrhythmias that have not responded to other treatments, including supraventricular tachycardia, junctional ectopic tachycardia, and ventricular tachycardia. A randomized, dose-response trial in 61 children (aged 30 days to nearly 15 years) found that the time to successful rhythm control was clearly dose-related. Adverse events were common, reported in 87 percent of patients, and included low blood pressure, vomiting, slow heart rate, and heart block. Five deaths occurred during the follow-up period, two of which were possibly related to the study drug.³² A separate review of 30 infants and children found intravenous amiodarone effective or partially effective in 94 percent of cases, with a median time to response of one day. Side effects occurred in over half the patients but did not require stopping the drug in any case.³³ Pediatric dosing and safety remain less established than in adults, and concerns about hypotension and excessive drug levels during continuous infusions persist.³⁴

Managing Side Effects Without Stopping the Drug

Given that amiodarone is often prescribed for arrhythmias where no good alternative exists, clinicians frequently face the question of whether to reduce the dose rather than stop it entirely. Many of the drug’s side effects, particularly the earlier toxic manifestations seen during high loading doses, respond to dose reduction within days to weeks. This is somewhat counterintuitive given how long the drug persists in tissues, but it appears that the concentration at the tissue level can shift enough with dose changes to make a clinical difference. Routine monitoring catches many problems while they are still mild and manageable. The practical reality for many patients is that the arrhythmia amiodarone controls is more immediately dangerous than the side effects it causes, making careful dose adjustment and organ surveillance a better strategy than abrupt discontinuation.

1
PubMed. Amiodarone: historical development and pharmacologic profile ↩︎
2
PubMed. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels ↩︎
3
The American Journal of Cardiology. Cellular Electropharmacology of Amiodarone ↩︎
4
PubMed. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome ↩︎
5
Journal of Cardiovascular Pharmacology. Amiodarone as Paradigm for Developing New Drugs for Atrial Fibrillation ↩︎
6
PubMed. Amiodarone to Prevent Recurrence of Atrial Fibrillation ↩︎
7
PubMed. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug ↩︎
8
PubMed. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation ↩︎
9
PubMed. Amiodarone dose in patients with shockable out-of-hospital cardiac arrest ↩︎
10
PubMed. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation ↩︎
11
PubMed. Amiodarone and cardiac arrest: Systematic review and meta-analysis ↩︎
12
PubMed Central / Journal of Hepatology. Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria ↩︎
13
PubMed Central. AMIODARONE AND THYROID DYSFUNCTION ↩︎
14
European Thyroid Journal. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction ↩︎
15
PubMed. Amiodarone: review of pulmonary effects and toxicity ↩︎
16
PubMed. Amiodarone: review of pulmonary effects and toxicity ↩︎
17
PubMed Central. Amiodarone pulmonary toxicity ↩︎
18
PubMed. Ocular effects in long-term amiodarone therapy ↩︎
19
PubMed Central. Amiodarone-associated optic neuropathy: a critical review ↩︎
20
PubMed. Amiodarone photosensitivity ↩︎
21
PubMed. Reversibility of blue-gray cutaneous discoloration from amiodarone ↩︎
22
PubMed. Amiodarone hepatotoxicity. A clinicopathologic study of five patients ↩︎
23
Human Pathology. Histopathologic analysis of suspected amiodarone hepatotoxicity ↩︎
24
PubMed. Clinical pharmacokinetics of amiodarone ↩︎
25
PubMed. Drug interactions with amiodarone ↩︎
26
PubMed Central. Adherence to Monitoring Guidelines of Amiodarone Adverse Reactions ↩︎
27
PubMed Central. Amiodarone-associated optic neuropathy: a critical review ↩︎
28
PubMed Central. Amiodarone vs Dronedarone for Atrial Fibrillation: A Retrospective Cohort Study ↩︎
29
PubMed. Safety and efficacy of amiodarone and dronedarone for early rhythm control in EAST-AFNET 4 ↩︎
30
PubMed. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment ↩︎
31
European Journal of Obstetrics & Gynecology and Reproductive Biology. Use of amiodarone during pregnancy ↩︎
32
PubMed. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial ↩︎
33
The American Journal of Cardiology. Clinical efficacy and safety of intravenous amiodarone in infants and children ↩︎
34
Archives of Disease in Childhood. Pharmacokinetics of intravenous amiodarone in children ↩︎